Some folks can view data from early, small clinical trials too skeptically or overly enthusiastically, and maybe that’s going on with some preliminary results from Verve Therapeutics. Good news? Bad news? I’m going to start with two articles about the same news that have very different vibes. What do I think? On the whole, I […]
Weekly reads: Verve Therapeutics, Casgevy UK OK, GDNF, MYC Read More »
For me, this was another week of heavy grant writing but also taking on Google again. How? Over how badly its search engine often performs on stem cell queries. I have a new piece at MedPage Today. It’s focused on the problem of Google Search promoting unproven stem cell clinic websites. Google still prefers stem
Weekly reads: Google, CIRM, young Swedish bone marrow Read More »
What’s more important than Woolly Mammoth de-extinction research in the stem cell arena? Only maybe a 10,000 other things. Still, the mammoth de-extinction efforts capture people’s attention much more than the average research story. Mammoth De-extinction update Is de-extinction only a pipette dream? This startup has a big, expensive plan to find out, Popular Science.
A days ago the news came about Mesoblast not getting FDA approval for its MSC product for GvHD. The MSC area has had a rough few years with various clinical trials including for COVID. The “stem cells for heart disease” arena has also had a tough time. Here’s more news along these lines: BioCardia pauses enrollment in PhIII trial
Weekly reads: BioCardia, HeLa suit, illegal bio lab in CA Read More »
Altos Labs is an intriguing multi-institution experiment in so-called rejuvenation research all rolled into one biotech. This relatively new entity headquartered in California has multiple Nobel laureates in the biomedical field in leadership. Even more importantly it has a large group of great researchers leading its individual research labs. This all leads to high expectations,
Some surprises from new analysis of Altos Labs papers Read More »
The Bay Area biotech Conception Bio has an intriguing name. What does “conception” mean here? Scientists can make many things from stem cells. For example, lately I’ve written a lot about stem cell-based human embryo models. Another intriguing area is called in vitro gametogenesis or IVG, where Conception Bio is a leader. IVG means making
Weekly reads: Conception Bio & IVG, MYC, Stanford Prez resigns Read More »
The biotech Sarepta has had a complicated go of it with the FDA sometimes related to their Duchenne muscular dystrophy (DMD) gene therapy efforts. In late 2016 I wrote about how there was some controversy as the FDA approved the Sarepta drug eteplirsen (Exondys 51) also for DMD, going against an advisory panel that had
Weekly reads: Sarepta, epigenomics, FDA on eyedrops Read More »
Today’s post takes a close look at the exosome manufacturer Kimera Labs in the context of the main exosome companies. What are exosomes? Exosomes are microscopic bubbles or vesicles produced by cells. Exosomes contain many cellular substances that are biologically active. Some of these materials may be helpful clinically, while others could pose risks. Clinical outcomes
Review of where Kimera Labs fits into sphere of exosome companies Read More »
It’s funny how sometimes there are many new articles about one general topic like this week with heritable (and somatic) human CRISPR gene editing and related tech. There are clear reasons for optimism in the somatic arena given advancing trials. Germline editing remains highly questionable in my view even just technically. Then there are loads
Weekly reads: human CRISPR, MRT risks, private IRBs, skincare Read More »
Near-billionaire Bryan Johnson apparently does not like getting old and he’s trying to do something transformative about it. He and his team are experimenting in a big way. As a 55-year-old myself, I can’t blame him for wanting to fight aging in general. However, his anti-aging project includes some extreme stuff. Will some in the
Skepticism on the Bryan Johnson anti-aging extravaganza Read More »